



Figure 3-8. Reverse phase HPLC purification of  $[^3H]$ 3-azioctanol labeled fragments from an EndoLysC digest of  $\alpha$ V8-20 and sequence analysis of HPLC fractions

A. αV8-20 isolated from nAChRs photolabeled with 275 μM [<sup>3</sup>H]3-azioctanol in the absence (●) or presence of 10 μM αBgTx (▼) or 2 mM carbamylcholine (○) was digested with EndoLysC. The digest was applied to a Brownlee Aquapore C4 column and fractionated by reverse-phase HPLC. Upper panel, <sup>3</sup>H elution profiles (5% of each fraction counted). Lower panel, fluorescence ("") and absorbance profiles (—). B, C.  ${}^{3}$ H ( $\bullet$ ,  $\circ$ ,  $\vee$ ) and mass released ( $\blacksquare$ ,  $\square$ ,  $\diamond$ ) on N-terminal sequencing of material in HPLC fraction 33 (B) and 29 (C). B, Fraction 33 from the sample labeled in the absence  $(\bullet, \blacksquare)$  and presence of carbamylcholine  $(\bigcirc, \square)$  showed a single sequence, beginning at  $\alpha$ Met-243, the N-terminus of the  $\alpha$ M2 segment (–carb:  $I_0$ =23 pmol, R=92%, 9800 cpm loaded, 3900 cpm remaining after 30 cycles; +carb: I<sub>0</sub>=30 pmol, R=92%, 26000 cpm loaded, 3900 cpm remaining after 30 cycles). C, Fraction 29 from the sample labeled in the absence  $(\bullet, \blacksquare)$  or presence of  $\alpha BgTx(\nabla, \bullet)$  or carbamylcholine  $(\bigcirc, \square)$  showed a primary sequence beginning at  $\alpha$ His-186 and a secondary sequence beginning at αAsp-180 (–carb: αHis-186 I<sub>0</sub>=35 pmol, R=93%, αAsp-180 I<sub>0</sub>=4.6 pmol, R=86%, 16700 cpm loaded, 3400 cpm remaining after 25 cycles;  $+\alpha BgTx$ :  $\alpha His-186 I_0=55 pmol, R=93\%, <math>\alpha Asp-180 I_0=2.4 pmol, R=95\%, 4100 cpm$ loaded, 1000 cpm remaining after 25 cycles; +carb: αHis-186 I<sub>0</sub>=36 pmol, R=95%,  $\alpha$ Asp-180 I<sub>0</sub>=7.8 pmol, R=82%, 4800 cpm loaded, 1200 cpm remaining after 25 cycles). Primary sequence for each fraction is shown on top axes.